RC-3095 TFA is a selective bombesin / gastrin releasing peptide receptor ( GRPR ) antagonist RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice . In Vivo RC-3095 impairs aversive but not recognition memory in Wistar male rats . RC-3095 (0.3 mg/kg or 1 mg/kg; S.C.) shows anti-inflammatory effects in 2 experimental models of arthritis, collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA). Arthritic mice treated with RC-3095 show a significant reduction in the concentrations of IL-17, IL-1 , and TNF, and showed a diminished expression of GRPR. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Balb/c wild-type mice (weighing 18-25 gm) with AIA model; Male DBA/1J inbred mice (weighing 18-25 gm) with CIA modelDosage: 1 mg/kg for AIA studies; 0.3 mg/kg or 1 mg/kg for CIA studies Administration: Injected SC twice a day for a total of 2 or 10 days for AIA studies; Administered SC twice a day for 10 days after the onset of the disease for CIA studies Result: Reduced neutrophil migration, mechanical hy pernociception, and proteoglycan loss in mice with AIA; Led to a significant reduction in arthritis clinical scores and the severity of disease in the CIA model. Form:Solid IC50& Target:Bombesin receptor,GRPR